An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease

2020 ◽  
Vol 21 (14) ◽  
pp. 1659-1665
Author(s):  
Thomas Müller
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subcutaneous Apomorphine

Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

1993 ◽  
Vol 8 (2) ◽  
pp. 165-170 ◽  
Author(s):  
A. J. Hughes ◽  
Susan Bishop ◽  
Birgit Kleedorfer ◽  
Nora Turjanski ◽  
W. Fernandez ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Chronic Administration ◽  
Disease Response ◽  
Subcutaneous Apomorphine

SIDE-EFFECTS OF SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE

The Lancet ◽  
1989 ◽  
Vol 333 (8646) ◽  
pp. 1084-1085 ◽  
Author(s):  
Werner Poewe ◽  
Birgit Kleedorfer ◽  
Michaela Wagner ◽  
Thomas Benke ◽  
Thomas Gasser ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Subcutaneous Apomorphine

scholarly journals Subcutaneous apomorphine in the treatment of Parkinson's disease.

1990 ◽  
Vol 53 (2) ◽  
pp. 96-101 ◽  
Author(s):  
J P Frankel ◽  
A J Lees ◽  
P A Kempster ◽  
G M Stern
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subcutaneous Apomorphine

SUBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASE

The Lancet ◽  
1988 ◽  
Vol 332 (8622) ◽  
pp. 1260 ◽  
Author(s):  
K. Ray Chaudhuri ◽  
P. Critchley ◽  
R.J. Abbott ◽  
I.F. Pye ◽  
P.A.H. Millac
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subcutaneous Apomorphine

The Treatment of Parkinson's Disease in Older People

1997 ◽  
Vol 42 (5) ◽  
pp. 147-150 ◽  
Author(s):  
C.T.C. Lien ◽  
W.J. Mutch
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Older People ◽  
Older Patients ◽  
Dopamine Agonists ◽  
Life Time ◽  
Comt Inhibitors ◽  
Functional Benefit ◽  
Subcutaneous Apomorphine ◽  
Variable Combination

Parkinson's disease is characterised by a variable combination of tremor, rigidity, bradykinesia and impaired righting reflexes. The cumulative life-time risk is one in 40. Levodopa remains the single most effective treatment in older patients, and the minimum dose to achieve maxiumu functional benefit should be employed. When fluctuations occur, controlled release preparations and selegiline can improve function. Oral dopamine agonists have a role but the combined side effect profile with levodopa should be monitored. COMT inhibitors have recently become available. Subcutaneous apomorphine can be helpful when “on-off phenomema are marked. The concept of neuroprotection continues to be debated. Surgery is an option for fitter older people but neurotransplantation remains essentially a research tool.

Sign in / Sign up

Export Citation Format

Share Document